Sudoterb/Rifampicin/Isoniazid/Pyrazinamide

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameSudoterb/Rifampicin/Isoniazid/Pyrazinamide
Drug Alias NameRifampicin/Isoniazid/Pyrazinamide/SudoterbPyrazinamide/Sudoterb/Rifampicin/IsoniazidLL-4858LL-3522
ClassificationSmall molecules
Mechanisms of ActionFatty acid synthase inhibitorsBacterial DNA-directed RNA polymerase inhibitors
TargetsFatty acid synthaseBacterial DNA-directed RNA polymerase
Therapy Area/IndicationsTuberculosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes SudoterbRifampicinIsoniazid
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLupin Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLupin Ltd
Active IndicationsN/A
Inactive IndicationsTuberculosis

Other Information

ATC CodeN/A
Related LinksN/A